{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:21:31Z","timestamp":1792178491614,"version":"4.4.0"},"reference-count":110,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2025,12,14]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Chimeric antigen receptor T cells (CAR-T cells) have revolutionised cancer treatment by offering personalised therapy of unprecedented efficacy to patients with relapsed B-cell malignancies and myeloma. CAR-T cells are designed selectively to target CD19 or other B-cell antigens with high affinity, leading to a potent immune response and effective killing of malignant B cells. More recently, CAR-T treatment has been shown to be safe and effective in a very limited number of patients with severe, refractory autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis and myositis. This paper describes the early use and feasibility of CAR-T therapies in the treatment of refractory autoimmune neurological diseases.<\/jats:p>","DOI":"10.1136\/pn-2025-004890","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:20:37Z","timestamp":1767723637000},"page":"414-425","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T cells in the treatment of neurological autoimmune diseases"],"prefix":"10.1136","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct04561557","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03605238","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06452537","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05063162","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04561557","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06588491","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3993-046X","authenticated-orcid":false,"given":"Frederick W","family":"Vonberg","sequence":"first","affiliation":[{"name":"Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, England, UK"},{"name":"Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Wales, Cardiff, Wales, UK"},{"name":"Department of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, Wales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Royal London Hospital, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Y","family":"Keh","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Salford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Ashraghi","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Joe","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital NHS Foundation Trust, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Gorgoraptis","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Royal London Hospital, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Rees","sequence":"additional","affiliation":[{"name":"Department of Neuro-oncology, National Hospital for Neurology and Neurosurgery, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-4549","authenticated-orcid":false,"given":"Nicholas W S","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chelsea and Westminster Hospital, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Finnerty","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital NHS Foundation Trust, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Willis","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Wales, Cardiff, Wales, UK"},{"name":"Department of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, Wales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Leite","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremias","family":"Motte","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling S","family":"Carr","sequence":"additional","affiliation":[{"name":"Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, England, UK"},{"name":"Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2102-6053","authenticated-orcid":false,"given":"Stephen","family":"Keddie","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Royal London Hospital, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026092100401129000_26.5.414.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"2026092100401129000_26.5.414.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2026092100401129000_26.5.414.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10237-3"},{"key":"2026092100401129000_26.5.414.4","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002550"},{"key":"2026092100401129000_26.5.414.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333924"},{"key":"2026092100401129000_26.5.414.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051414","article-title":"CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression","volume":"15","author":"Luksik","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092100401129000_26.5.414.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"2026092100401129000_26.5.414.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1"},{"key":"2026092100401129000_26.5.414.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2026092100401129000_26.5.414.10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"The Lancet"},{"key":"2026092100401129000_26.5.414.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2026092100401129000_26.5.414.12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"2026092100401129000_26.5.414.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"2026092100401129000_26.5.414.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2216"},{"key":"2026092100401129000_26.5.414.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-018-0019-6"},{"key":"2026092100401129000_26.5.414.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.021"},{"key":"2026092100401129000_26.5.414.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026092100401129000_26.5.414.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"2026092100401129000_26.5.414.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.021"},{"key":"2026092100401129000_26.5.414.20","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026092100401129000_26.5.414.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026092100401129000_26.5.414.22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.14740\/jh903","article-title":"Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma","volume":"10","author":"Ahrendsen","year":"2021","journal-title":"J Hematol"},{"key":"2026092100401129000_26.5.414.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6"},{"key":"2026092100401129000_26.5.414.24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026092100401129000_26.5.414.25","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026092100401129000_26.5.414.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w"},{"key":"2026092100401129000_26.5.414.27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"2026092100401129000_26.5.414.28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"2026092100401129000_26.5.414.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7"},{"key":"2026092100401129000_26.5.414.30","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.jtct.2023.12.532","article-title":"Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)","volume":"30","author":"van de Donk","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"2026092100401129000_26.5.414.31","doi-asserted-by":"crossref","unstructured":"Miller L , Barrell K . Peripheral and Cranial Neuropathies Following CAR-T Cell Therapy for Multiple Myeloma: A Case Series (S16.006). Neurology (ECronicon) 2025;104. doi:10.1212\/WNL.0000000000210768","DOI":"10.1212\/WNL.0000000000210768"},{"key":"2026092100401129000_26.5.414.32","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2021004889","article-title":"Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma","volume":"5","author":"Jung","year":"2021","journal-title":"Blood Adv"},{"key":"2026092100401129000_26.5.414.33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61683","article-title":"Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"8","author":"Camacho-Arteaga","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092100401129000_26.5.414.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103126"},{"key":"2026092100401129000_26.5.414.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"2026092100401129000_26.5.414.36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2026092100401129000_26.5.414.37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2026092100401129000_26.5.414.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2026092100401129000_26.5.414.39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026092100401129000_26.5.414.40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012637"},{"key":"2026092100401129000_26.5.414.41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"2026092100401129000_26.5.414.42","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00375-7"},{"key":"2026092100401129000_26.5.414.43","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026092100401129000_26.5.414.44","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026092100401129000_26.5.414.45","doi-asserted-by":"crossref","unstructured":"Faissner S , Motte J , Sgodzai M , et al . Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci USA 2024;121. doi:10.1073\/pnas.2403227121","DOI":"10.1073\/pnas.2403227121"},{"key":"2026092100401129000_26.5.414.46","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026092100401129000_26.5.414.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.08.005"},{"key":"2026092100401129000_26.5.414.48","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"2026092100401129000_26.5.414.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011"},{"key":"2026092100401129000_26.5.414.50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170"},{"key":"2026092100401129000_26.5.414.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads8473"},{"key":"2026092100401129000_26.5.414.52","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020002547"},{"key":"2026092100401129000_26.5.414.53","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"2026092100401129000_26.5.414.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z"},{"key":"2026092100401129000_26.5.414.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.10.001"},{"key":"2026092100401129000_26.5.414.56","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.ymthe.2025.06.042","article-title":"CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes","volume":"33","author":"Ruck","year":"2025","journal-title":"Mol Ther"},{"key":"2026092100401129000_26.5.414.57","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front Neurol"},{"key":"2026092100401129000_26.5.414.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501561"},{"key":"2026092100401129000_26.5.414.59","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"2026092100401129000_26.5.414.60","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z"},{"key":"2026092100401129000_26.5.414.61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026092100401129000_26.5.414.62","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"2026092100401129000_26.5.414.63","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1"},{"key":"2026092100401129000_26.5.414.64","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"2026092100401129000_26.5.414.65","doi-asserted-by":"crossref","unstructured":"Motte J , Klimas R , Sgodzai M , et al . Treatment of Three Autoimmune Neuropathies with Autologous CD19-Targeted CAR-T Cells (S18.002). Neurology (ECronicon) 2025;104. doi:10.1212\/WNL.0000000000211837","DOI":"10.1212\/WNL.0000000000211837"},{"key":"2026092100401129000_26.5.414.66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.23288","article-title":"POEMS syndrome: Update on diagnosis, risk\u2010stratification, and management","volume":"87","author":"Dispenzieri*","year":"2012","journal-title":"American J Hematol"},{"key":"2026092100401129000_26.5.414.67","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000796","article-title":"Comprehensive Diagnosis and Management of POEMS Syndrome","volume":"6","author":"D\u2019Sa","year":"2022","journal-title":"Hemasphere"},{"key":"2026092100401129000_26.5.414.68","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000486","article-title":"Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome","volume":"5","author":"Pihan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026092100401129000_26.5.414.69","doi-asserted-by":"crossref","unstructured":"Xu J , Wang Q , Xu H , et al . Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol 2018;11. doi:10.1186\/s13045-018-0672-7","DOI":"10.1186\/s13045-018-0672-7"},{"key":"2026092100401129000_26.5.414.70","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11111721","article-title":"CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond","volume":"11","author":"Mishra","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2026092100401129000_26.5.414.71","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1212\/WNL.0000000000009940","article-title":"Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study","volume":"95","author":"Keddie","year":"2020","journal-title":"Neurology"},{"key":"2026092100401129000_26.5.414.72","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1182\/bloodadvances.2020003176","article-title":"Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy","volume":"4","author":"Jhaveri","year":"2020","journal-title":"Blood Adv"},{"key":"2026092100401129000_26.5.414.73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7150\/ijms.38363","article-title":"Progress in Hematopoietic Stem Cell Transplantation for CIDP","volume":"17","author":"Qin","year":"2020","journal-title":"Int J Med Sci"},{"key":"2026092100401129000_26.5.414.74","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306014"},{"key":"2026092100401129000_26.5.414.75","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1111\/bjh.16057","article-title":"High-dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise?","volume":"186","author":"Tomkins","year":"2019","journal-title":"Br J Haematol"},{"key":"2026092100401129000_26.5.414.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.021"},{"key":"2026092100401129000_26.5.414.77","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2006","journal-title":"Brain (Bacau)"},{"key":"2026092100401129000_26.5.414.78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2026092100401129000_26.5.414.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2026092100401129000_26.5.414.80","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30342-2"},{"key":"2026092100401129000_26.5.414.81","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"The Lancet"},{"key":"2026092100401129000_26.5.414.82","doi-asserted-by":"crossref","unstructured":"Gupta S , Simic M , Sagan SA , et al . CAR-T Cell\u2013Mediated B-Cell Depletion in Central Nervous System Autoimmunity. Neurol Neuroimmunol Neuroinflamm 2023;10. doi:10.1212\/NXI.0000000000200080","DOI":"10.1212\/NXI.0000000000200080"},{"key":"2026092100401129000_26.5.414.83","doi-asserted-by":"crossref","unstructured":"Mullard A . CAR-T therapy for multiple sclerosis enters US trials for first time. Nature New Biol 2024. doi:10.1038\/d41586-024-00470-5","DOI":"10.1038\/d41586-024-00470-5"},{"key":"2026092100401129000_26.5.414.84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026092100401129000_26.5.414.85","doi-asserted-by":"crossref","unstructured":"Paul F , Marignier R , Palace J , et al . International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Neurol Neuroimmunol Neuroinflamm 2023;10. doi:10.1212\/NXI.0000000000200124","DOI":"10.1212\/NXI.0000000000200124"},{"key":"2026092100401129000_26.5.414.86","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/WCO.0000000000000828","article-title":"Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics","volume":"33","author":"Fujihara","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2026092100401129000_26.5.414.87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"2026092100401129000_26.5.414.88","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"2026092100401129000_26.5.414.89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"2026092100401129000_26.5.414.90","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z"},{"key":"2026092100401129000_26.5.414.91","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515587752"},{"key":"2026092100401129000_26.5.414.92","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"2026092100401129000_26.5.414.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.02.012"},{"key":"2026092100401129000_26.5.414.94","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet"},{"key":"2026092100401129000_26.5.414.95","doi-asserted-by":"crossref","unstructured":"Kim S-H , Jang H , Park NY , et al . Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol Neuroinflamm 2021;8. doi:10.1212\/NXI.0000000000000947","DOI":"10.1212\/NXI.0000000000000947"},{"key":"2026092100401129000_26.5.414.96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026092100401129000_26.5.414.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2020.10.005"},{"key":"2026092100401129000_26.5.414.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2023.06.009"},{"key":"2026092100401129000_26.5.414.99","doi-asserted-by":"crossref","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"2026092100401129000_26.5.414.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102696"},{"key":"2026092100401129000_26.5.414.101","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25648"},{"key":"2026092100401129000_26.5.414.102","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325300"},{"key":"2026092100401129000_26.5.414.103","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.neurol.2024.08.003","article-title":"Predicting the future of autoimmune encephalitides","volume":"180","author":"Guasp","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2026092100401129000_26.5.414.104","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J Neurol"},{"key":"2026092100401129000_26.5.414.105","doi-asserted-by":"crossref","unstructured":"Shang H , Shen X , Yu X , et al . B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential. Front Immunol 2024;15. doi:10.3389\/fimmu.2024.1368275","DOI":"10.3389\/fimmu.2024.1368275"},{"key":"2026092100401129000_26.5.414.106","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/ene.13759","article-title":"Plasma cell depletion with bortezomib in the treatment of refractory N \u2010methyl\u2010 d \u2010aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment","volume":"25","author":"Keddie","year":"2018","journal-title":"Euro J of Neurology"},{"key":"2026092100401129000_26.5.414.107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","article-title":"Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology","volume":"82","author":"Ismail","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026092100401129000_26.5.414.108","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000001270","article-title":"Mechanisms of autoimmune encephalitis","volume":"37","author":"Papi","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"2026092100401129000_26.5.414.109","doi-asserted-by":"crossref","first-page":"100776","DOI":"10.1016\/j.medj.2025.100776","article-title":"Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis","volume":"6","author":"Hegelmaier","year":"2025","journal-title":"Med"},{"key":"2026092100401129000_26.5.414.110","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2023-003974"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2025-004890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:27:56Z","timestamp":1790522876000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2025-004890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":110,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,20]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/pn-2025-004890"],"URL":"https:\/\/doi.org\/10.1136\/pn-2025-004890","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}